+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neurodegenerative Diseases Market by Disease Type, Treatment Type, Treatment Stage, Route of Administration, End User - Global Forecast to 2030- Product Image
Neurodegenerative Diseases Market by Disease Type, Treatment Type, Treatment Stage, Route of Administration, End User - Global Forecast to 2030- Product Image
Sale

Neurodegenerative Diseases Market by Disease Type, Treatment Type, Treatment Stage, Route of Administration, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6090380
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Neurodegenerative Diseases Market grew from USD 51.45 billion in 2024 to USD 55.33 billion in 2025. It is expected to continue growing at a CAGR of 7.90%, reaching USD 81.22 billion by 2030.

Shaping the Future of Neurodegenerative Disease Management

The burgeoning prevalence of neurodegenerative diseases has propelled this therapeutic area to the forefront of global healthcare priorities. As populations age and diagnostic capabilities improve, diseases such as Alzheimer’s and Parkinson’s are no longer siloed conditions but critical challenges that demand multisector collaboration. Healthcare providers, pharmaceutical developers, and policy makers are seeking cohesive, actionable intelligence to anticipate shifts in patient needs and funding paradigms.

This executive summary synthesizes the most salient trends shaping research, treatment, and care delivery for neurodegenerative conditions. It spotlights how evolving scientific breakthroughs and shifting regulatory environments are redefining commercial and clinical landscapes. By distilling complex dynamics into clear, strategic insights, this introduction lays the foundation for a deeper exploration of market forces-offering a compass for decision-makers who must navigate an intricate and fast-moving field.

Unveiling Pivotal Transition Points in Disease Treatment and Care

A wave of transformation is reshaping the neurodegenerative disease landscape, driven by technological advancements and novel therapeutic modalities. Pioneering gene therapies and targeted biologics are moving from preclinical stages into human trials, challenging traditional small-molecule strategies. At the same time, artificial intelligence-enabled diagnostics are accelerating early detection, enabling clinicians to intervene at the onset of cognitive decline rather than at irreversible stages.

Concurrently, patient-centric care models are gaining prominence. Integrated digital health platforms are facilitating remote monitoring of symptoms and treatment adherence, while multidisciplinary care teams are redefining standards of holistic support. This convergence of high-tech solutions and comprehensive care frameworks marks a pivotal shift: the industry is evolving from symptom management toward proactive disease modification.

Industry stakeholders must embrace these transitions to stay ahead. Pharmaceutical companies are reevaluating R&D portfolios, payers are exploring value-based reimbursement, and advocacy groups are amplifying patient voices. As a result, the market is no longer driven by incremental improvements; instead, it is defined by bold innovations that promise to alter the trajectory of neurodegeneration.

Assessing the Ripple Effects of 2025 US Tariff Adjustments

The imposition of new tariffs on imported medical devices and active pharmaceutical ingredients in 2025 has triggered a cascade of supply chain realignments. Manufacturers of injectables and specialized intrathecal formulations are adjusting sourcing strategies to mitigate increased costs, while some raw material suppliers are exploring domestic partnerships to maintain price competitiveness.

These tariff-driven adjustments have financial and operational implications. Clinical trial sponsors are recalibrating budgets to account for elevated import duties, potentially slowing down enrollment in studies that rely on overseas sourcing. Meanwhile, hospitals and long-term care facilities are renegotiating vendor contracts to preserve margin integrity. Payers are increasingly vigilant, scrutinizing cost structures and demanding transparent value propositions for high-cost treatments.

Yet these challenges also present opportunities for agility. Companies that diversify their supply chains-by establishing regional manufacturing hubs or qualifying secondary suppliers-can secure faster market entry and reduce exposure to tariff volatility. Strategic planning now requires an integrated view of global trade policies, ensuring that R&D pipelines and commercialization roadmaps remain resilient in the face of evolving economic barriers.

Deciphering Market Dynamics Through Multifaceted Segmentation Lens

Insight into market segmentation provides a foundational lens through which to interpret distinct growth vectors. By disease type, the market bifurcates into conditions such as Alzheimer’s Disease, which commands high research prioritization due to its prevalence in aging populations, and Amyotrophic Lateral Sclerosis, where therapeutic breakthroughs remain rare yet urgently needed. Frontotemporal Dementia and Multiple Sclerosis occupy niche pockets of innovation, each shaped by unique pathophysiology and clinical trial complexities, while Parkinson’s Disease continues to benefit from a robust pipeline of dopaminergic and gene-based therapies.

Treatment type segmentation further refines this picture. The landscape of non-pharmacological interventions now encompasses cognitive behavioral therapy tailored for memory impairment, occupational therapy protocols that maximize patient independence, physical therapy regimens designed to preserve motor function, and speech therapy approaches that address communication challenges. In parallel, pharmacological treatments are advancing across multiple classes: cholinesterase inhibitors remain a mainstay in early Alzheimer’s management, dopamine agonists and immunomodulatory drugs drive symptomatic relief in movement disorders, and emerging N-methyl-D-aspartate receptor antagonists offer new hope in slowing disease progression.

When viewed through the lens of treatment stage, distinct clinical and commercial strategies emerge. Early stage interventions prioritize diagnostics and preventative care; moderate stage therapies emphasize disease modification; and late stage solutions focus on palliation and quality-of-life maintenance. Routes of administration-ranging from injectables to intrathecal or intraventricular delivery and conventional oral dosing-further influence patient adherence, healthcare resource utilization, and manufacturing considerations. Finally, the end-user segment encompasses a spectrum of care settings. Home care environments demand user-friendly formulations and telehealth integration, hospitals and clinics require specialized administration capabilities, and long-term care facilities necessitate cost-effective, durable therapies that can be delivered by nursing staff. Together, these segmentation insights clarify the heterogeneity of patient journeys and highlight where targeted investments can yield the greatest strategic returns.

Regional Landscapes Driving Distinct Growth Trajectories

Regional analysis underscores how distinct economic, regulatory, and demographic forces drive market potential. In the Americas, robust healthcare infrastructure and favorable reimbursement frameworks have catalyzed rapid uptake of both pharmacological and non-pharmacological treatments, with patient advocacy networks amplifying access initiatives. However, price sensitivity remains a critical factor as payers push for demonstrable outcomes and cost-effective care models.

Europe, Middle East & Africa present a mosaic of regulatory environments, from stringent centralized approvals in the European Union to emerging frameworks in the Middle East and Africa that balance market access with local manufacturing ambitions. Advanced economies in Western Europe are witnessing a shift toward value-based procurement, while markets in the Gulf region and Sub-Saharan Africa are prioritizing capacity building and infrastructure investments to address growing disease burden.

In Asia-Pacific, rapid urbanization and expanding private healthcare sectors are stimulating demand for innovative therapies. Markets such as Japan and Australia benefit from established reimbursement pathways and aging populations, whereas Southeast Asian nations are fostering public-private partnerships to enhance diagnostic capabilities and clinical trial participation. Across the region, cost containment policies coexist with aggressive government initiatives aimed at accelerating domestic biopharmaceutical innovation.

Profiling Leading Innovators and Strategic Market Movements

Leading companies are forging diversified strategies that span early discovery to market access. Global pharmaceutical giants are leveraging their extensive R&D platforms and regulatory expertise to accelerate late-stage assets, while specialized biotech firms concentrate on niche modalities such as gene editing and cell-based therapies. Partnerships between academic institutions and industry players are proliferating, enabling seamless translation of preclinical discoveries into clinical candidates.

Some of the most notable strategic maneuvers include the pursuit of licensing agreements to broaden therapeutic portfolios and the establishment of center-of-excellence pilot programs for intrathecal delivery systems. Technology firms are also entering the space, contributing AI-driven analytics for patient stratification and trial optimization. Concurrently, contract research organizations are expanding service offerings to support complex neurodegeneration studies, from biomarker validation to real-world evidence generation.

To maintain momentum, companies are investing in stakeholder engagement initiatives that underscore value propositions to payers, clinicians, and patient communities. Transparent outcome data and adaptive clinical trial designs are increasingly employed to streamline regulatory pathways and secure earlier market entry.

Charting a Course Strategic Imperatives for Industry Advancement

Industry leaders must adopt a proactive posture to capitalize on emerging opportunities. First, integrating advanced diagnostics with companion therapeutics will differentiate product offerings and support premium pricing structures. Second, diversifying supply chains and localizing manufacturing footprints can buffer against policy shifts and improve time to market. Third, forging alliances with telehealth and digital therapeutics providers will create comprehensive care ecosystems that extend beyond traditional treatment modalities.

Payers and providers should collaborate on value-based agreements that tie reimbursement to real-world patient outcomes, thereby aligning incentives with the overarching goal of disease modification. In parallel, investment in training programs for multidisciplinary care teams can accelerate adoption of both pharmacological and non-pharmacological interventions, elevating standards of patient support.

Finally, leadership must champion patient-centric innovation by incorporating patient-reported outcomes into development strategies, ensuring that new therapies not only demonstrate clinical efficacy but also address quality-of-life metrics that matter most to caregivers and individuals living with neurodegenerative diseases.

Ensuring Rigor A Holistic Research Methodology Framework

Our research methodology is grounded in a rigorous synthesis of both primary and secondary data sources, structured to deliver a robust and unbiased market perspective. Secondary research included an exhaustive review of peer-reviewed journals, regulatory filings, conference proceedings, and industry databases to construct a foundational understanding of therapeutic landscapes and policy environments.

Primary research involved qualitative interviews and quantitative surveys with key stakeholders such as clinical researchers, payers, care providers, and patient advocacy leaders. Insights gleaned from these interactions were triangulated with secondary data to validate hypotheses and uncover emergent trends.

Data analysis employed cross-sectional and longitudinal techniques to map treatment adoption curves, compare regional regulatory trajectories, and assess competitive positioning. Ethical considerations and data integrity protocols were strictly adhered to, ensuring compliance with global standards for research transparency and reproducibility.

Synthesizing Insights for Informed Decision Making

In conclusion, the neurodegenerative disease market is at a transformative juncture characterized by scientific innovation, evolving care paradigms, and shifting policy landscapes. Addressing the complexities of treatment segmentation, regional diversity, and supply chain resilience is critical for stakeholders aiming to deliver meaningful patient outcomes while sustaining commercial viability.

By synthesizing the current state of research, tariff impacts, and regional variations, this executive summary offers a strategic blueprint for navigating the multifaceted challenges of this domain. Decision-makers equipped with these insights will be better positioned to chart a path toward more effective therapies and integrated care models that meet the urgent needs of patients worldwide.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Disease Type
    • Alzheimer’s Disease
    • Amyotrophic Lateral Sclerosis
    • Frontotemporal Dementia
    • Multiple Sclerosis
    • Parkinson’s Disease
  • Treatment Type
    • Non-Pharmacological Interventions
      • Cognitive Behavioral Therapy
      • Occupational Therapy
      • Physical Therapy
      • Speech Therapy
    • Pharmacological Treatments
      • Cholinesterase Inhibitors
      • Dopamine Agonists
      • Immunomodulatory Drugs
      • N-methyl-D-aspartate Receptor Antagonists
  • Treatment Stage
    • Early Stage
    • Late Stage
    • Moderate Stage
  • Route of Administration
    • Injectables
    • Intrathecal/Intraventricular
    • Oral
  • End User
    • Home Care
    • Hospitals & Clinics
    • Long-Term Care Facilities
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • AbbVie Inc.
  • Amgen Inc.
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • GW Pharmaceuticals plc
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Lundbeck A/S
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Neurocrine Biosciences, Inc.
  • Otsuka Holdings Co., Ltd.
  • Roche Holding AG
  • Sanofi SA
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting

5. Market Dynamics

6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Neurodegenerative Diseases Market, by Disease Type
8.1. Introduction
8.2. Alzheimer’s Disease
8.3. Amyotrophic Lateral Sclerosis
8.4. Frontotemporal Dementia
8.5. Multiple Sclerosis
8.6. Parkinson’s Disease

9. Neurodegenerative Diseases Market, by Treatment Type
9.1. Introduction
9.2. Non-Pharmacological Interventions
9.2.1. Cognitive Behavioral Therapy
9.2.2. Occupational Therapy
9.2.3. Physical Therapy
9.2.4. Speech Therapy
9.3. Pharmacological Treatments
9.3.1. Cholinesterase Inhibitors
9.3.2. Dopamine Agonists
9.3.3. Immunomodulatory Drugs
9.3.4. N-methyl-D-aspartate Receptor Antagonists

10. Neurodegenerative Diseases Market, by Treatment Stage
10.1. Introduction
10.2. Early Stage
10.3. Late Stage
10.4. Moderate Stage

11. Neurodegenerative Diseases Market, by Route of Administration
11.1. Introduction
11.2. Injectables
11.3. Intrathecal/Intraventricular
11.4. Oral

12. Neurodegenerative Diseases Market, by End User
12.1. Introduction
12.2. Home Care
12.3. Hospitals & Clinics
12.4. Long-Term Care Facilities

13. Americas Neurodegenerative Diseases Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina

14. Europe, Middle East & Africa Neurodegenerative Diseases Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland

15. Asia-Pacific Neurodegenerative Diseases Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan

16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AbbVie Inc.
16.3.2. Amgen Inc.
16.3.3. Bayer AG
16.3.4. Biogen Inc.
16.3.5. Bristol-Myers Squibb Company
16.3.6. Eli Lilly and Company
16.3.7. GlaxoSmithKline plc
16.3.8. GW Pharmaceuticals plc
16.3.9. Ionis Pharmaceuticals, Inc.
16.3.10. Johnson & Johnson Services, Inc.
16.3.11. Lundbeck A/S
16.3.12. Merck & Co., Inc.
16.3.13. Mitsubishi Tanabe Pharma Corporation
16.3.14. Neurocrine Biosciences, Inc.
16.3.15. Otsuka Holdings Co., Ltd.
16.3.16. Roche Holding AG
16.3.17. Sanofi SA
16.3.18. Sumitomo Dainippon Pharma Co., Ltd.
16.3.19. Takeda Pharmaceutical Company Limited
16.3.20. Teva Pharmaceutical Industries Ltd.
16.3.21. UCB S.A.

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

List of Figures
FIGURE 1. NEURODEGENERATIVE DISEASES MARKET MULTI-CURRENCY
FIGURE 2. NEURODEGENERATIVE DISEASES MARKET MULTI-LANGUAGE
FIGURE 3. NEURODEGENERATIVE DISEASES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS NEURODEGENERATIVE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS NEURODEGENERATIVE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES NEURODEGENERATIVE DISEASES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES NEURODEGENERATIVE DISEASES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC NEURODEGENERATIVE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC NEURODEGENERATIVE DISEASES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. NEURODEGENERATIVE DISEASES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. NEURODEGENERATIVE DISEASES MARKET, FPNV POSITIONING MATRIX, 2024

List of Tables
TABLE 1. NEURODEGENERATIVE DISEASES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY ALZHEIMER’S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY FRONTOTEMPORAL DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY PARKINSON’S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY OCCUPATIONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY SPEECH THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY DOPAMINE AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY IMMUNOMODULATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY N-METHYL-D-ASPARTATE RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY LATE STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY MODERATE STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY INTRATHECAL/INTRAVENTRICULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL NEURODEGENERATIVE DISEASES MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS NEURODEGENERATIVE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES NEURODEGENERATIVE DISEASES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 53. CANADA NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 54. CANADA NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 55. CANADA NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 56. CANADA NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 57. CANADA NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 58. CANADA NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. CANADA NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. MEXICO NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 61. MEXICO NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 62. MEXICO NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 63. MEXICO NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 64. MEXICO NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 65. MEXICO NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. MEXICO NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 89. UNITED KINGDOM NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 91. UNITED KINGDOM NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 92. UNITED KINGDOM NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 93. UNITED KINGDOM NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. GERMANY NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 97. GERMANY NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 98. GERMANY NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 99. GERMANY NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 100. GERMANY NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 101. GERMANY NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. GERMANY NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. FRANCE NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 104. FRANCE NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 105. FRANCE NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 106. FRANCE NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 107. FRANCE NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 108. FRANCE NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. FRANCE NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. RUSSIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 111. RUSSIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 112. RUSSIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 113. RUSSIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 114. RUSSIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 115. RUSSIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. RUSSIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. ITALY NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 118. ITALY NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 119. ITALY NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 120. ITALY NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 121. ITALY NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 122. ITALY NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. ITALY NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. SPAIN NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 125. SPAIN NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 126. SPAIN NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 127. SPAIN NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 128. SPAIN NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 129. SPAIN NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. SPAIN NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 132. UNITED ARAB EMIRATES NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 133. UNITED ARAB EMIRATES NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 134. UNITED ARAB EMIRATES NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 135. UNITED ARAB EMIRATES NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 136. UNITED ARAB EMIRATES NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. UNITED ARAB EMIRATES NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. SAUDI ARABIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 139. SAUDI ARABIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 140. SAUDI ARABIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 141. SAUDI ARABIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 142. SAUDI ARABIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 143. SAUDI ARABIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. SAUDI ARABIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. SOUTH AFRICA NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 146. SOUTH AFRICA NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 147. SOUTH AFRICA NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 148. SOUTH AFRICA NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 149. SOUTH AFRICA NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 150. SOUTH AFRICA NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 151. SOUTH AFRICA NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. DENMARK NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 153. DENMARK NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 154. DENMARK NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 155. DENMARK NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 156. DENMARK NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 157. DENMARK NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. DENMARK NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. NETHERLANDS NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 161. NETHERLANDS NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 162. NETHERLANDS NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 163. NETHERLANDS NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 164. NETHERLANDS NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. NETHERLANDS NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. QATAR NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 167. QATAR NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 168. QATAR NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 169. QATAR NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 170. QATAR NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 171. QATAR NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. QATAR NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. FINLAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 174. FINLAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 175. FINLAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 176. FINLAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 177. FINLAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 178. FINLAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. FINLAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 182. SWEDEN NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 183. SWEDEN NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 184. SWEDEN NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 185. SWEDEN NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. SWEDEN NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. NIGERIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 188. NIGERIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 189. NIGERIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 190. NIGERIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 191. NIGERIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 192. NIGERIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. NIGERIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. EGYPT NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 195. EGYPT NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 196. EGYPT NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 197. EGYPT NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 198. EGYPT NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 199. EGYPT NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 200. EGYPT NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. TURKEY NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 202. TURKEY NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 203. TURKEY NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 204. TURKEY NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 205. TURKEY NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 206. TURKEY NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. TURKEY NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. ISRAEL NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 210. ISRAEL NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 211. ISRAEL NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 212. ISRAEL NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 213. ISRAEL NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. ISRAEL NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. NORWAY NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 216. NORWAY NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 217. NORWAY NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 218. NORWAY NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 219. NORWAY NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 220. NORWAY NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 221. NORWAY NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. POLAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 223. POLAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 224. POLAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 225. POLAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 226. POLAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 227. POLAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. POLAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. SWITZERLAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 230. SWITZERLAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 231. SWITZERLAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 232. SWITZERLAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 233. SWITZERLAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 234. SWITZERLAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. SWITZERLAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 241. ASIA-PACIFIC NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 242. ASIA-PACIFIC NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. ASIA-PACIFIC NEURODEGENERATIVE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 244. CHINA NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 245. CHINA NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 246. CHINA NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 247. CHINA NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 248. CHINA NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 249. CHINA NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 250. CHINA NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. INDIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 252. INDIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 253. INDIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 254. INDIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 255. INDIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 256. INDIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 257. INDIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. JAPAN NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 259. JAPAN NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 260. JAPAN NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 261. JAPAN NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 262. JAPAN NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 263. JAPAN NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. JAPAN NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 267. AUSTRALIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 268. AUSTRALIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 269. AUSTRALIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 270. AUSTRALIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. AUSTRALIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 274. SOUTH KOREA NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 275. SOUTH KOREA NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 276. SOUTH KOREA NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 277. SOUTH KOREA NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 278. SOUTH KOREA NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 281. INDONESIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 282. INDONESIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 283. INDONESIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 284. INDONESIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 285. INDONESIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. THAILAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 287. THAILAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 288. THAILAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 289. THAILAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 290. THAILAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 291. THAILAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 292. THAILAND NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 293. PHILIPPINES NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 294. PHILIPPINES NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 295. PHILIPPINES NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 296. PHILIPPINES NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2030 (USD MILLION)
TABLE 297. PHILIPPINES NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
TABLE 298. PHILIPPINES NEURODEGENERATIVE DISEASES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 299. PHILIPPINES NEURODEGENERATIVE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 300. MALAYSIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 301. MALAYSIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 302. MALAYSIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
TABLE 303. MALAYSIA NEURODEGENERATIVE DISEASES MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018

Companies Mentioned

The companies profiled in this Neurodegenerative Diseases market report include:
  • AbbVie Inc.
  • Amgen Inc.
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • GW Pharmaceuticals plc
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Lundbeck A/S
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Neurocrine Biosciences, Inc.
  • Otsuka Holdings Co., Ltd.
  • Roche Holding AG
  • Sanofi SA
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages199
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 55.33 Billion
Forecasted Market Value ( USD ) by 2030 $ 81.22 Billion
Compound Annual Growth Rate7.9%
Regions CoveredGlobal
No. of Companies Mentioned22

Related Topics

Related Reports

Neurodegenerative Drugs Market by Type, Drug Class, Mode Of Administration, Mechanism Of Action, Therapeutic Approach, Indication, Patient Demographics, Sales Channel, End User - Global Forecast to 2030 - Product Image

Neurodegenerative Drugs Market by Type, Drug Class, Mode Of Administration, Mechanism Of Action, Therapeutic Approach, Indication, Patient Demographics, Sales Channel, End User - Global Forecast to 2030

  • Report
  • 188 Pages
  • Global
From
Neurodegenerative Disease Treatment Market Report by Indication, Drug Type, Route of Administration, Distribution Channel, and Region 2024-2032 - Product Image

Neurodegenerative Disease Treatment Market Report by Indication, Drug Type, Route of Administration, Distribution Channel, and Region 2024-2032

  • Report
  • 135 Pages
  • Global
From
Neurodegenerative Diseases Therapeutics - Global Strategic Business Report - Product Image

Neurodegenerative Diseases Therapeutics - Global Strategic Business Report

  • Report
  • 387 Pages
  • Global
From
Mild Cognitive Impairment Market - Product Image

Mild Cognitive Impairment Market

  • Report
  • 250 Pages
  • Global
From
Neurodegenerative Diseases Drugs Market Report and Forecast 2024-2032 - Product Image

Neurodegenerative Diseases Drugs Market Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.